The potential of deep learning: generating drug targets
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
List view / Grid view
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
Culture conditions during embryoid body formation can be enhanced to gain glia-associated proteins and neural network activity.
Researchers showed that ESI1, or similar compounds, may help to slow or even reverse cognitive losses that can occur during aging.
Researchers found that genetic depletion of cyclophilin A results in stem cells distinctively lacking intrinsically disordered proteins.
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
The discovery of three m6A modifications and their exact locations could lead to the development of drugs that inhibit viral RNA and protein production.
In this Q&A, Associate Professor Dr Mete Civelek shares insights from the University of Virginia’s exciting recent study identifying several potential therapeutic targets for accelerating translational research in cardiovascular disease treatment, with a focus on proteins associated with the extracellular matrix (ECM) secretion by smooth muscle cells (SMCs).
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
Dr Fernández-Capetillo shares his insights from a recent study conducted at the CNIO, elucidating how the expression of (PR)arginine-rich peptides affects ribosomal protein translation and accumulation, and how accelerated aging can be alleviated.
IFNβ could be developed into a new therapy, following an improved understanding of how innate immunity affects the brain during chronic HIV infection.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The discovery of two proteins that effectively mature hiPSCs into endothelial cells may have a range of research and clinical benefits.
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
Researchers discover that fusion proteins and a gene regulatory protein complex interact through disordered domains.